Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on...

Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX'
Conference on Tuesday, August 19th at 1:30 p.m. PDT

LA JOLLA, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that its CEO, James
S. Kuo, M.D., M.B.A. will present at the fourth annual Noble Financial Equity
Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in
Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr.
Kuo will also be available for one-on-one meetings throughout the day.
The presentation with streaming video and PowerPoint will be webcast live
and archived on Noble Financial's conference website at
http://www.noblemadmax.com. Participants should register at least 10 minutes
prior to the start of the presentation to ensure timely access.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company
that develops new cardiovascular medicines based upon the emerging new
pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
molecules play critical roles in cellular metabolism and signal transduction,
the manipulation of which by several pharmaceuticals constitute novel
therapeutic modalities for the treatment of major cardiovascular disorders.
Duska is developing a portfolio of investigational medicines, two of which are
in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a
pivotal Phase 3 clinical trial for the treatment of paroxysmal
supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase
2 clinical trial for the treatment of heart failure. In addition, Duska has a
preclinical program to develop new chemical entities that target a newly
discovered pathway in the pathophysiology of chronic obstructive pulmonary
disease. For more information, visit http://www.duskatherapeutics.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended that involve
risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements. The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," or variations of such words are
intended to identify such forward-looking statements. All statements in this
release regarding the future outlook related to Duska are forward-looking
statements, including the statements that Duska will present at the fourth
annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the
Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is
scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one
meetings throughout the day. The forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements. Additional
uncertainties and risks are described in Duska's most recently filed SEC
documents, such as its most recent annual report on Form 10-KSB, all quarterly
reports on Form 10-QSB and any current reports on Form 8-K filed since the
date of the last Form 10-KSB. Copies of these filings are available through
the SEC website at http://www.sec.gov. All forward-looking statements are
based upon information available to Duska on the date hereof. Duska undertakes
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, other than
as required by law.
SOURCE Duska Therapeutics, Inc.

James S. Kuo, M.D., M.B.A., Chairman and CEO of Duska Therapeutics, Inc.,
+1-858-551-5700, Fax, +1-858-551-5704, kuoj@duskascientific.com